Related Experiment Video
Updated: Dec 24, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Small-molecule PROTACs: novel agents for cancer therapy
Yichao Wan1, Chunxing Yan1, Han Gao1
1Key Laboratory of Theoretical Organic Chemistry & Functional Molecule, Ministry of Education, Hunan Provincial Key Laboratory of Controllable Preparation & Functional Application of Fine Polymers, School of Chemistry & Chemical Engineering, Hunan University of Science & Technology, Xiangtan, Hunan, 411201, PR China.
Proteolysis-targeting chimeras (PROTACs) offer a novel approach to selectively degrade target proteins. This review highlights small-molecule PROTAC advancements and their potential in cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that leverage the ubiquitin-proteasome system for targeted protein degradation.
- PROTACs offer advantages over traditional inhibitors, including enhanced potency, selectivity, and overcoming drug resistance.
Purpose of the Study:
- To review the mechanism of PROTACs.
- To summarize the progress of small-molecule PROTACs utilizing various E3 ligases.
- To discuss the opportunities and challenges of small-molecule PROTACs in cancer therapy.
Main Methods:
- Literature review focusing on small-molecule PROTAC development.
- Analysis of PROTAC mechanisms and applications.
- Examination of E3 ligase utilization in PROTAC design.
Main Results:
- PROTAC technology enables selective protein degradation through the ubiquitin-proteasome pathway.
- Significant advancements have been made in small-molecule PROTACs over the past two decades.
- Various E3 ligases are being explored to broaden PROTAC applicability.
Conclusions:
- Small-molecule PROTACs represent a promising therapeutic strategy for cancer treatment.
- Further research is needed to address the challenges and optimize PROTACs for clinical use.
- PROTACs offer a new paradigm in targeted protein degradation for drug development.
More Related Videos
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer
Drugs that Stabilize Microtubules
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy